Paper · 42885282

Glycyrrhizic acid attenuates corneal inflammation and pathological angiogenesis through FAK/PI3K/AKT signaling.

Yu J and 7 others. Mol Med Rep, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Glycyrrhizic acid attenuates corneal inflammation and pathological angiogenesis through FAK/PI3K/AKT signaling. Papers, record 42885282. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42885282

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Glycyrrhizic acid attenuates corneal inflammation and pathological angiogenesis through FAK/PI3K/AKT signaling.
Journal: Mol Med Rep
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42885282/
DOI: https://doi.org/10.3892/mmr.2026.14046
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13712100/
The journal: https://conductscience.org/library/journal-index/101475259
Revised in PubMed: 2026-10-29

Source PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Yu J	Jinjin
2	Qu H	Huiheng
3	Fang Y	Yinming
4	Xu W	Weicheng
5	Ding N	Nannan
6	Ji J	Jie
7	Wang N	Nan
8	Shi W	Wei

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Proto-Oncogene Proteins c-akt	Major topic
Signal Transduction	Major topic
Glycyrrhizic Acid	Major topic
Phosphatidylinositol 3-Kinases	Major topic
Corneal Neovascularization	Major topic
Neovascularization, Pathologic	Major topic
Animals
Humans
Mice
Male
Human Umbilical Vein Endothelial Cells
Focal Adhesion Protein-Tyrosine Kinases
Burns, Chemical
Disease Models, Animal
Cornea
Focal Adhesion Kinase 1
Cell Proliferation
Wound Healing
Eye Burns
Inflammation

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	38,366,136	Self-Organization of Long-Lasting Human Endothelial Capillary-Like Networks Guided by DLP Bioprinting.	Adv Healthc Mater	2024	https://conductscience.org/library/papers/38366136	PubMed
2	36,739,832	Upadacitinib inhibits corneal inflammation and neovascularization by suppressing M1 macrophage infiltration in the corneal alkali burn model.	Int Immunopharmacol	2023	https://conductscience.org/library/papers/36739832	PubMed
3	35,600,640	Ferrostatin-1-loaded liposome for treatment of corneal alkali burn via targeting ferroptosis.	Bioeng Transl Med	2022	https://conductscience.org/library/papers/35600640	PubMed
4	32,633,407	Glycyrrhizin improves inflammation and apoptosis via suppressing HMGB1 and PI3K/mTOR pathway in lipopolysaccharide-induced acute liver injury.	Eur Rev Med Pharmacol Sci	2020	https://conductscience.org/library/papers/32633407	PubMed
5	28,226,245	Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation.	Biomaterials	2017	https://conductscience.org/library/papers/28226245	PubMed
6	21,860,391	Molecular control of endothelial cell behaviour during blood vessel morphogenesis.	Nat Rev Mol Cell Biol	2011	https://conductscience.org/library/papers/21860391	PubMed
7	41,649,225	AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways.	Invest Ophthalmol Vis Sci	2026	https://conductscience.org/library/papers/41649225	PubMed
8	25,183,764	The role of toll-like receptor 4 in corneal epithelial wound healing.	Invest Ophthalmol Vis Sci	2014	https://conductscience.org/library/papers/25183764	PubMed
9	37,458,425	A Mouse Model for Corneal Neovascularization by Alkali Burn.	J Vis Exp	2023	https://conductscience.org/library/papers/37458425	PubMed
10	32,527,252	Mechanism of Heshouwuyin inhibiting the Cyt c/Apaf-1/Caspase-9/Caspase-3 pathway in spermatogenic cell apoptosis.	BMC Complement Med Ther	2020	https://conductscience.org/library/papers/32527252	PubMed

1 to 10 of 60

See all 60 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42885282

GET https://conductscience.org/api/papers/v1/42885282/references?page=2

API reference For AI assistants